Related references
Note: Only part of the references are listed.Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan- European TOCERRA register collaboration
Kim Lauper et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study
Brigitte Michelsen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study
Natalia Mena-Vazquez et al.
RHEUMATOLOGY INTERNATIONAL (2017)
Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs
Jennifer H. Lofland et al.
PATIENT PREFERENCE AND ADHERENCE (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
Cem Gabay et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Rheumatoid arthritis: current and future trends
Kritika Chaudhari et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Evolution of Patient Decision-Making Regarding Medical Treatment of Rheumatoid Arthritis
Alexandra L. Mathews et al.
ARTHRITIS CARE & RESEARCH (2016)
Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis
J. E. Gottenberg et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study
D. S. Courvoisier et al.
EBIOMEDICINE (2016)
Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
Marie-Elise Truchetet et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
Elena Nikiphorou et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
Hubert G. Nuesslein et al.
BMC MUSCULOSKELETAL DISORDERS (2015)
Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry
Cem Gabay et al.
RHEUMATOLOGY (2015)
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
M. Neovius et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
Sofia Ramiro et al.
RMD OPEN (2015)
The Status of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Not Associated with the Effect of Anti-TNFα Agent Treatment in Patients with Rheumatoid Arthritis: A Meta-Analysis
Qianwen Lv et al.
PLOS ONE (2014)
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules
Ryoko Sakai et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
The effect of smoking on response and drug survival in rheumatoid arthritis patients treated with their first anti-TNF drug
M. K. Soderlin et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2012)
Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of north america cohort of rheumatoid arthritis patients
Damini Jawaheer et al.
ARTHRITIS CARE & RESEARCH (2012)
Interleukin-6 Receptor Inhibition With Tocilizumab and Attainment of Disease Remission in Rheumatoid Arthritis The Role of Acute-Phase Reactants
Josef S. Smolen et al.
ARTHRITIS AND RHEUMATISM (2011)
Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis
Pengxiang Li et al.
VALUE IN HEALTH (2010)
Comparison of Drug Retention Rates and Causes of Drug Discontinuation Between Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis
Sophie Martin Du Pan et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Predictors of response to anti-TNF-α therapy among patients with rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Register
K. L. Hyrich et al.
RHEUMATOLOGY (2006)
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
Lars Erik Kristensen et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period
JJ Gomez-Reino et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Share Paper
